A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
Clinical trial NCT03975647 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03975647
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-10-02
- Primary completion
- 2023-06-29
- Enrollment
- 466
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.